文献速递生殖医学

脆性X综合征患者及前突变携带者接受体外受精-胚胎植入前遗传学诊断时的卵巢反应:再评估

The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal.
PubMed 文献 · Hum Reprod · 2017-01-01

本研究回顾性分析了21例FMR1全突变患者和51例前突变携带者共309个新鲜IVF-PGD周期的卵巢反应。前突变携带者获卵数(8.4±1.1)低于全突变患者(14.1±1.7,P=0.005),雌二醇水平亦较低(1756±177 vs 2928±263,P=0.0004);前突变携带者中CGG重复数与获卵数无显著关联。

要点

  • 前突变携带者卵巢反应降低,获卵数8.4±1.1 vs 全突变患者14.1±1.7(P=0.005)。
  • 前突变携带者雌二醇水平较低:1756±177 vs 2928±263(P=0.0004)。
  • 前突变携带者中CGG重复数与获卵数、雌二醇水平无显著关联。

核心结论

  • 全突变患者卵巢反应正常,而前突变携带者卵巢反应降低,但CGG重复数与获卵数无统计学显著关联。

研究设计与样本

  • 回顾性研究,大学附属三级医院IVF中心及PGD转诊中心,纳入21例FMR1全突变患者和51例前突变携带者,共分析309个新鲜IVF-PGD周期。

主要发现

  • 前突变携带者每周期平均获卵数8.4±1.1,全突变患者14.1±1.7(P=0.005)。
  • 前突变携带者雌二醇水平1756±177,全突变患者2928±263(P=0.0004)。
  • 前突变携带者与全突变患者的受精率、卵裂率及活检率无显著差异。
  • 前突变携带者中CGG重复数与获卵数或雌二醇水平无相关性。
  • 前突变携带者中仅年龄(P=0.037)和方案类型(P=0.003)与获卵数相关。

临床怎么用

  • 作者认为医生必须关注携带者卵巢反应降低和早发性卵巢功能不全(POI)风险增加,并考虑监测卵巢储备标志物,可能加速家庭计划完成或生育力保存。

局限性

  • CGG重复数>100的前突变携带者数量相对较少,难以从该组得出确切结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the association between the ovarian response and the number of CGG repeats among full mutation and premutation carriers of fragile X (FMR1), undergoing controlled ovarian hyperstimulation (COH) for PGD? SUMMARY ANSWER: Ovarian response was normal in full mutation patients but decreased in premutation carriers, although the number of repeats was not statistically significantly associated with the number of oocytes retrieved. WHAT IS KNOWN ALREADY: There is inconsistent data in the literature regarding ovarian response in FMR1 carriers. Studies exploring the ovarian response of full mutation patients are lacking. STUDY DESIGN, SIZE, DURATION: Retrospective study, a university affiliated tertiary hospital, IVF unit, PGD referral center. PARTICIPANTS/MATERIALS, SETTING, METHODS: We examined the medical records of all women undergoing fresh IVF-PGD cycles due to fragile X. Data recorded included demography, duration of stimulation, amount of gonadotropins administered, number of dominant follicles, maximal E2 levels and number of oocytes retrieved. Data were analyzed using univariate and multivariate mixed models. P-values <0.05 were considered significant. Data were collected from the medical records of 21 patients with a full mutation on the FMR1 gene and 51 premutation carriers. Overall 309 fresh cycles were analyzed. MAIN RESULTS AND THE ROLE OF CHANCE: Premutation carriers displayed reduced ovarian response, as demonstrated by fewer oocytes retrieved. In contrast, full mutation patients had a normal response. Comparison of premutation carriers and full mutation patients showed: mean oocytes retrieved per cycle (8.4 ± 1.1 versus 14.1 ± 1.7, P = 0.005), lower levels of estradiol (E2; 1756 ± 177, versus 2928 ± 263, P = 0.0004), respectively. There was no significant difference between premutation carriers and full mutation patients in regard to fertilization rate, cleavage rate or biopsy rate. No correlation was found between the number of repeats in the premutation carriers and the number of oocytes retrieved or E2 levels. Age and the type of protocol were the only factors found to be in correlation with the number of the oocyte retrieved (P = 0.037, and P = 0.003, respectively) among the premutation carriers. Similarly, no association was found between the number of repeats and the fertilization rate, cleavage rate or biopsy rate among premutation carriers. LIMITATIONS, REASONS FOR CAUTION: We had a relatively low number of premutation carriers with >100 repeats, which made it challenging to draw a firm conclusions from this group. WIDER IMPLICATIONS OF THE FINDINGS: Physicians must address the increased risk for reduced ovarian response and primary ovarian insufficiency (POI) among carriers and consider surveillance of ovarian reserve markers. The last, might expedite family plans completion or fertility preservation. STUDY FUNDING/COMPETING INTEREST(S): None.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Avraham S, Almog B, Reches A, et al. The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal. Hum Reprod. 2017. PMID: 28472405. doi:10.1093/humrep/dex090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。